Want to see NL:CRBN full AI Analyst Report?
Top Page
Corbion NV
(CRBN)
Select Model
Select Model
Rating:63Neutral
Price Target:
€29.00
▲(46.32% Upside)
Action:Reiterated
Date:10/28/26
The score is driven primarily by improving financial quality (deleveraging and sustained positive operating cash flow/free cash flow), partially offset by multi-year revenue decline and uneven earnings. Technicals add support due to a strong uptrend, but overbought readings temper the outlook. Valuation is a further drag given the ~25 P/E with only a moderate dividend yield.
Positive Factors
Deleveraging
Material debt reduction strengthens Corbion’s balance sheet and lowers financial risk relative to prior years. Greater equity support and reduced leverage should improve resilience, preserve borrowing capacity, and give management more flexibility to fund operations and strategic growth.
Negative Factors
Multi-Year Revenue Decline
Several years of revenue contraction indicate that Corbion has not yet established a durable growth trajectory. Continued top-line pressure can limit operating leverage, reduce resources available for innovation, and make earnings improvement more dependent on pricing, mix, or cost actions.
Read all positive and negative factors
Positive Factors
Negative Factors
Deleveraging
Material debt reduction strengthens Corbion’s balance sheet and lowers financial risk relative to prior years. Greater equity support and reduced leverage should improve resilience, preserve borrowing capacity, and give management more flexibility to fund operations and strategic growth.
Read all positive factors
Corbion NV (CRBN) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€1.58B
Dividend Yield2.47%
Average Volume (3M)164.40K
Price to Earnings (P/E)25.4
Beta (1Y)0.97
Revenue Growth-3.37%
EPS Growth-8.22%
CountryNL
Employees2,363
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)1.08
Shares Outstanding58,250,310
10 Day Avg. Volume265,359
30 Day Avg. Volume164,402
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)1.45
Price to Sales (P/S)0.85
P/FCF Ratio11.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.00Price Target Upside66.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.36
Revenue Forecast (FY)€1.30B
Corbion NV Business Overview & Revenue Model
Company Description
Corbion NV engages in the development, production, sale, and distribution of ingredients for food and biochemicals. It operates through the following segments: Food and Biochemicals. The Food segment provides biobased ingredients for the food indu...
How the Company Makes Money
Corbion makes money primarily by manufacturing and selling ingredient and material products to business customers (B2B), with revenue largely tied to volumes sold and pricing under supply agreements.
1) Food-related ingredients (preservation and ...
Corbion NV Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
63
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.27B | 1.29B | 1.26B | 1.46B | 1.07B |
| Gross Profit | 313.90M | 334.70M | 319.60M | 284.20M | 326.40M | 269.00M |
| EBITDA | 186.40M | 204.20M | 177.40M | 147.20M | 184.40M | 132.60M |
| Net Income | 62.20M | 74.80M | 192.20M | 72.90M | 90.00M | 78.30M |
Balance Sheet | ||||||
| Total Assets | 1.49B | 1.42B | 1.55B | 1.70B | 1.72B | 1.36B |
| Cash, Cash Equivalents and Short-Term Investments | 36.00M | 44.70M | 49.30M | 70.20M | 58.20M | 42.20M |
| Total Debt | 517.60M | 481.10M | 509.20M | 785.50M | 759.20M | 503.20M |
| Total Liabilities | 733.30M | 674.30M | 773.80M | 1.06B | 1.10B | 806.50M |
| Stockholders Equity | 755.70M | 742.60M | 772.50M | 636.20M | 625.70M | 554.10M |
Cash Flow | ||||||
| Free Cash Flow | 75.60M | 92.70M | 99.90M | 16.10M | -182.60M | -122.00M |
| Operating Cash Flow | 144.20M | 160.90M | 184.10M | 165.40M | 53.20M | 26.70M |
| Investing Cash Flow | -69.50M | -70.10M | 166.00M | -146.80M | -213.30M | -123.70M |
| Financing Cash Flow | -79.50M | -93.80M | -371.70M | -5.30M | 173.90M | 85.90M |
Corbion NV Technical Analysis
Positive
19.82
Price Trends
22.53
Positive
21.26
Positive
19.98
Positive
Market Momentum
1.19
Negative
75.18
Negative
74.68
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:CRBN, the sentiment is Positive. The current price of 19.82 is below the 20-day moving average (MA) of 23.87, below the 50-day MA of 22.53, and below the 200-day MA of 19.98, indicating a bullish trend. The MACD of 1.19 indicates Negative momentum. The RSI at 75.18 is Negative, neither overbought nor oversold. The STOCH value of 74.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:CRBN.
Corbion NV Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | €25.56B | -22.15 | ― | 2.34% | -44.75% | -301.20% | |
64 Neutral | €679.08M | 11.59 | 13.37% | 6.10% | -2.56% | -15.44% | |
63 Neutral | €1.58B | 25.35 | 8.30% | 2.47% | -3.37% | -8.22% | |
62 Neutral | €6.03B | 26.22 | 11.06% | 1.77% | 2.64% | -14.83% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
52 Neutral | €864.69M | -73.17 | -13.87% | 17276.13% | ― | ― | |
41 Neutral | €134.98M | -1.53 | -25.04% | ― | -32.85% | 26.72% |
* General Sector Average
NL:CRBN
Corbion NV
27.38
10.63
63.50%
NL:ACOMO
Acomo N.V.
22.95
0.30
1.32%
NL:AVTX
Avantium N.V.
2.30
-1.76
-43.40%
NL:IMCD
IMCD N.V.
102.25
15.92
18.44%
NL:OCI
OCI N.V.
4.10
0.67
19.66%
NL:DSFIR
DSM-Firmenich AG
106.75
39.56
58.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.